Protocol for the insight study: a randomised controlled trial of single-dose tocilizumab in patients with depression and low-grade inflammation by Khandaker, GM et al.
1Khandaker GM, et al. BMJ Open 2018;8:e025333. doi:10.1136/bmjopen-2018-025333
Open access 
Protocol for the insight study: a 
randomised controlled trial of single-
dose tocilizumab in patients with 
depression and low-grade inflammation
Golam M Khandaker,1,2 Bianca P Oltean,1,2 Muzaffer Kaser,1,2 Claire R M Dibben,3 
Rajini Ramana,1,2 Deepak R Jadon,4 Robert Dantzer,5 Alasdair J Coles,6 
Glyn Lewis,7 Peter B Jones1,2
To cite: Khandaker GM, 
Oltean BP, Kaser M, et al.  
Protocol for the insight 
study: a randomised 
controlled trial of single-dose 
tocilizumab in patients with 
depression and low-grade 
inflammation. BMJ Open 
2018;8:e025333. doi:10.1136/
bmjopen-2018-025333
 ► Prepublication history and 
additional material for this paper 
are available online. To view 
please visit the journal (http:// 
dx. doi. org/ 10. 1136/ bmjopen- 
2018- 025333).
Received 10 July 2018
Revised 14 August 2018
Accepted 16 August 2018
For numbered affiliations see 
end of article.
Correspondence to
Dr Golam M Khandaker;  
 gmk24@ medschl. cam. ac. uk
Protocol
© Author(s) (or their 
employer(s)) 2018. Re-use 
permitted under CC BY. 
Published by BMJ.
AbstrACt
Introduction Observational studies indicate a potentially 
causal role for interleukin 6 (IL-6), a proinflammatory 
cytokine, in pathogenesis of depression, but interventional 
studies based on patients with depression have not 
been conducted. Tocilizumab, anti-inflammatory drug, 
is a humanised monoclonal antibody that inhibits IL-6 
signalling and is licensed in the UK for treatment of 
rheumatoid arthritis. The main objectives of this study 
are to test whether IL-6 contributes to the pathogenesis 
of depression and to examine potential mechanisms 
by which IL-6 affects mood and cognition. A secondary 
objective is to compare depressed participants with and 
without evidence of low-grade systemic inflammation.
Methods and analysis This is a proof-of-concept, 
randomised, parallel-group, double-blind, placebo-
controlled clinical trial. Approximately 50 participants 
with International Classification of Diseases 10th revision 
(ICD-10) diagnosis of depression who have evidence of 
low-grade inflammation, defined as serum high-sensitivity 
C reactive protein (hs-CRP) level ≥3 mg/L, will receive 
either a single intravenous infusion of tocilizumab or 
normal saline. Blood samples, behavioural and cognitive 
measures will be collected at baseline and after infusion 
around day 7, 14 and 28. The primary outcome is somatic 
symptoms score around day 14 postinfusion. In addition, 
approximately, 50 depressed participants without low-
grade inflammation (serum hs-CRP level <3 mg/L) 
will complete the same baseline assessments as the 
randomised cohort.
Ethics and dissemination The study has been 
approved by the South Central—Oxford B Research 
Ethics Committee (REC) (Reference: 18/SC/0118). Study 
findings will be published in peer-review journals. Findings 
will be also disseminated by conference/departmental 
presentations and by social and traditional media.
trial registration number ISRCTN16942542; Pre-results.
IntroduCtIon 
scientific background and study rationale
Low-grade systemic inflammation as reflected 
by elevated concentrations of circulating 
inflammatory markers in peripheral blood 
may play a role in pathogenesis of depres-
sion.1 2 Meta-analysis of cross-sectional studies 
confirms that concentrations of circulating 
inflammatory cytokines, such as interleukin 
6 (IL-6) and acute phase proteins, such as 
C reactive protein (CRP), are elevated in 
acutely unwell patients with depression,3–5 
which tend to normalise after recovery5 but 
continue to be elevated in treatment resistant 
patients.6 7 Experimental studies indicate IL-6 
and other cytokines are important mediators 
of the effects of inflammation on the brain.1 2 
However, it is unclear whether inflammation 
plays a causal role in depression because 
cytokine elevation could be a consequence 
of depression (ie, reverse causality) or due 
to confounding. Existing epidemiological 
studies have addressed these issues to some 
extent (below), but randomised controlled 
trials (RCTs) of anticytokine treatment in 
depression are scarce. Intervention studies 
targeting the IL-6 system are required for 
a better understanding of the relationship 
between inflammation and depression.
strengths and limitations of this study
 ► This is one of the first studies to examine the role 
of interleukin 6 in patients with depression using a 
randomised controlled trial design.
 ► The study examines important intermediate mark-
ers for antidepressant effect including somatic 
symptoms of depression, which will provide mech-
anistic insights into potential role of inflammation in 
depression.
 ► Comparison between inflamed and non-inflamed 
patients will help to better characterise patients with 
inflammation-related depression.
 ► As single dose of tocilizumab will be used, the study 
may not be able to test conclusively the efficacy of 
tocilizumab as potential treatment for depression.
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Population-based longitudinal studies showing an asso-
ciation between elevated concentrations of IL-6 or CRP 
at baseline and increased risk of depression at follow-up 
indicates reverse causality is an unlikely explanation for 
previously observed association between IL-6 and depres-
sion.8–11 Using data from the Avon Longitudinal Study of 
Parents and Children (ALSPAC) birth cohort, we have 
reported that elevated concentrations of serum IL-6 in 
childhood are associated with increased risk of depression 
subsequently in early adulthood in a linear, dose–response 
fashion9 (figure 1A). Evidence for this association remains 
after controlling for potential confounders including sex, 
body mass index and maternal depression. This is one 
of the first evidence from humans that low-grade inflam-
mation precedes depression, so is unlikely to be simply a 
consequence of illness.
Results from genetic association analysis informed 
by Mendelian randomisation (MR) indicate residual 
confounding is unlikely to explain the association between 
IL-6 and depression fully. MR is based on the idea that if 
a biomarker is causally related to an illness, genetic vari-
ant(s) regulating levels/activity of that biomarker should 
also be associated with the illness.12 13 Genetic variants 
segregate at random during meiosis and are unrelated 
to potential confounders, so using them as markers of 
exposure could overcome confounding. Using data from 
the ALSPAC birth cohort, we have shown that a genetic 
variant in the IL-6 receptor gene (IL-6R Asp358Ala; 
rs2228145) that is known to dampen down inflammation 
by impairing the activity of IL-6 is protective for severe 
depression14 (figure 1B). The genetic variant is strongly 
associated with serum IL-6 and CRP levels, but not with 
any common confounders of the inflammation–depres-
sion relationship such as sex, social class, ethnicity and 
body mass index. These findings strongly indicate that 
the IL-6/IL-6R pathways play a role in the pathophysi-
ology of depression.
Although human population-based observational 
studies strongly support an association between IL-6 
and depression, observational studies cannot confirm 
causality. RCTs are needed to test whether manipula-
tion of IL-6 signalling has an impact on depressive symp-
toms in individuals with depression, but such studies are 
lacking. RCTs could also elucidate potential mechanisms 
by which IL-6 affects mood and cognition. Inflammation 
is unlikely to be relevant for all patients with depression,15 
so consideration is required regarding the choice of suit-
able patients and outcomes for clinical trials of anti-in-
flammatory treatment to elucidate potential mechanistic 
role of the IL-6 system in depression (below).
stratified patient selection and choice of outcomes
A meta-analysis has reported that anticytokine drugs 
improve depressive symptoms in patients with chronic 
inflammatory illness, such as rheumatoid arthritis, inde-
pendently of improvement in physical illness.16 Similarly, 
an RCT of infliximab (anti-Tumour Necrosis Factor alpha 
(TNF-α) monoclonal antibody and anti-inflammatory 
drug), which excluded patients with chronic physical 
illness, reported that the drug is more likely to improve 
depressive symptoms in patients with depression who 
show evidence of low-grade inflammation (ie, elevated 
CRP levels) at baseline.17 Therefore, clinical trials of IL-6 
modulation should focus on depressed participants who 
have evidence of low-grade inflammation. Patients who 
do not get better with antidepressants are more likely to 
show evidence of low-grade inflammation.6 7
Figure 1 Cases of depression at age 18 in the ALSPAC birth cohort grouped by serum IL-6 levels at age 9 (A) and by IL-6R 
genotype (B). (A) Samples of depression were divided by tertiles of interleukin 6 (IL-6) in participants at age 9 years. Cut-off 
values for the top and bottom thirds of the distribution of IL-6 values in the total sample (cases and non-cases combined) 
were 1.08 and 0.57 pg/mL, respectively (reproduced with permission from Khandaker et al9). Panel (B) has been adapted from 
Khandaker et al.10ALSPAC, Avon Longitudinal Study of Parents and Children; IL-6R, interleukin 6 receptor.
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Inflammatory cytokines are more likely to be relevant 
for somatic symptoms of depression (eg, fatigue, appe-
tite and sleep disturbance) rather than psychological 
symptoms (eg, hopelessness). Fatigue, sleep disturbance 
develop rapidly in majority of interferon-treated patients 
with cancer who develop depression (an established 
human model for inflammation-induced depression), 
but cognitive and affective symptoms (eg, impaired 
memory, low mood) develop slowly and relatively less 
frequently.18 19 Population-based studies have shown that 
elevated serum IL-6 and CRP levels are associated with 
fatigue, impaired sleep, but not with hopelessness.20 21 
Cytokine-induced somatic symptoms may affect mood by 
reducing rewarding experiences,22 so could be a mediator 
of the relationship between inflammation and depres-
sion. This idea is consistent with our own work from the 
ALSPAC birth cohort which indicates that somatic symp-
toms mediate the association between IL-6 and psycho-
logical symptoms.23 Other groups have also reported that 
somatic symptoms of depression are associated with CRP, 
IL-6 and TNF-α levels.24 Therefore, somatic symptoms 
could be useful treatment target and marker of treatment 
response in clinical trials of anti-inflammatory treatment 
for depression. However, to our knowledge, no interven-
tional study has examined the effects of reducing IL-6 
activity on somatic symptoms specifically in individuals 
with depression.
Cognitive dysfunction, an unmet treatment need in 
depression,25 could be related to inflammation. Preclin-
ical studies suggest that IL-6 may mediate inflamma-
tion-induced cognitive dysfunction in rats and mice.26 27 
Neuroinflammation is associated with depressive symp-
toms and increased production of inflammatory cyto-
kines in the hippocampus, a brain structure critical for 
memory.28 At population level, associations between 
circulating IL-6, CRP and general intelligence29 and 
cognitive symptoms of depression8 have been reported. 
In patients with depression, higher inflammatory marker 
levels are associated with poor psychomotor speed30 31 and 
persistent cognitive dysfunction.32 Therefore, in addition 
to depressive symptoms, inclusion of measures of cogni-
tive function could provide useful insights into potential 
role of inflammation in depression.
Proposed study
We propose a proof-of-concept, randomised, paral-
lel-group, double-blind, placebo controlled clinical trial 
to investigate whether IL-6 contributes to pathogenesis 
of depression and to examine potential mechanisms by 
which IL-6 affects mood and cognition. We propose that 
inhibition of IL-6 signalling in individuals with depres-
sion who show evidence of low-grade inflammation and 
poor response to antidepressants would attenuate their 
depressive symptoms particularly somatic symptoms of 
depression.
Patients with depression who show evidence of inflam-
mation may be different from those who do not. Those 
with low-grade inflammation are likely to be antidepressant 
resistant,6 7 so a clearer understanding of this group would 
be clinically useful. We also propose an observational study 
to examine similarities and differences between patients 
with depression with and without low-grade inflammation.
study AIMs And hyPothEsIs
Primary
To carry out a proof-of-concept, randomised, paral-
lel-group, double-blind, placebo-controlled clinical 
trial to test whether IL-6 contributes to pathogenesis of 
depression and to examine potential mechanisms by 
which IL-6 affects mood and cognition. We hypothesise 
that inhibition of IL-6 signalling with a single intravenous 
infusion of anti-IL6R monoclonal antibody tocilizumab 
will attenuate somatic symptoms of depression, improve 
cognitive function, reduce serum proinflammatory cyto-
kine levels and indoleamine 2,3-dioxygenase (IDO) acti-
vation in individuals with depression who show evidence 
of low-grade inflammation and poor response to anti-
depressant. Low-grade inflammation, hereafter also 
referred to as ‘inflamed depression’, will be defined as 
serum high-sensitivity CRP (hs-CRP) level ≥3 mg/L.
secondary
To carry out an observational study to examine differ-
ences and similarities between inflamed and non-in-
flamed depression (CRP <3 mg/L). We hypothesise that 
individuals with inflamed depression, compared with 
non-inflamed, will be more likely to have somatic symp-
toms, higher levels of serum proinflammatory cytokines, 
cognitive dysfunction and evidence of IDO activation.
MEthods
This protocol has been prepared in accordance with the 
Standard Protocol Items: Recommendations for Interven-
tional Trials (SPIRIT) 2013 statement.33 Please see online 
supplementary eTable 1 for the SPIRIT checklist.
Patient and public involvement
Patients were consulted during the development of the 
study protocol who contributed to the procedure, consent 
form and information leaflets. The study information was 
made more accessible and data collection assessments 
shorter. Interested participants will receive a summary of 
the main findings at the end of the study.
study design and sample
The study has two parts. The clinical trial part will 
include approximately 50 patients with depression 
with CRP ≥3 mg/L (intervention cohort) who will be 
randomised into two groups (tocilizumab or normal 
saline). The observational part will compare the interven-
tion cohort at baseline with 50 non-inflamed depressed 
patients (CRP <3 mg/L). Non-inflamed patients will not 
be randomised. For an overview of the study design, 
please see figure 2.
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Intervention
The study intervention will be a single intravenous infusion 
of tocilizumab (8 mg/kg; max 800 mg/patient) or normal 
saline. Tocilizumab is the first-in-class, anti-IL-6R human-
ised monoclonal antibody, which is commercially available 
and licensed in the UK for treating rheumatoid arthritis 
and juvenile idiopathic arthritis. Tocilizumab blocks both 
IL-6 classic and trans-signalling (responsible for most of the 
inflammatory effects of IL-6) making it the agent of choice 
for complete IL-6 inhibition.34 As justified by interferon35 
and mouse36 studies, peripheral immune activation causes 
depression because IL-6 and other circulating cytokines can 
influence the brain using neural, humoral and cellular path-
ways.1 2 37 38 Therefore, tocilizumab which is mostly periph-
erally acting is likely to have an impact on symptoms of 
depression. Infliximab, an anti-TNF-α monoclonal antibody, 
that has similar, limited blood–brain barrier penetration as 
tocilizumab has been reported to modulate symptoms of 
depression.17 Similarly, peripherally acting anti-IL-6 mono-
clonal antibody has been reported to reduce depression-like 
behaviour in mice exposed to repeated stress.39
Eligibility criteria
The study will include adult participants aged 20–65 years 
meeting ICD-10 criteria40 for depressive episode who 
are currently taking an antidepressant at adequate dose 
(according to British National Formulary or BNF) for at 
least 4 weeks. In addition, those included in the clinical 
trial part will have serum hs-CRP levels ≥3 mg/L. Please 
see table 1 for complete inclusion and exclusion criteria.
outcome
The primary outcome is change in total somatic symptom 
score from baseline to around day 14 postinfusion assessed 
using the Beck Depression Inventory-II41 (BDI-II). The 
somatic symptom score will be constructed by summing 
scores for seven relevant BDI-II items (4=lack of plea-
sure, 15=loss of energy, 16=changes in sleeping pattern, 
18=changes in appetite, 19=concentration difficulty, 
20=tiredness or fatigue and 21=loss of interest in sex). 
Depression severity is secondary outcome also assessed 
by BDI-II. As an experimental medicine study, we will 
collect data on a range of tertiary/exploratory measures 
including, but not limited to, fatigue, anhedonia, cogni-
tive function and peripheral blood analyses of inflamma-
tory markers, cortisol and markers of IDO activation.
statistical power
No RCTs were available to inform a power calculation 
for the proposed primary outcome. However, the clinical 
Figure 2 Overview of design and procedures for the insight study. CRN, clinical research network; CPFT,  Cambridgeshire 
and Peterborough NHS Foundation Trust; GP, general practice; hs-CRP, high-sensitivity C reactive protein; NSFT, Norfolk and 
Suffolk NHS Foundation Trust. 
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trial (n=50) will have 80% statistical power (alpha=0.05) 
to detect a 2.5-point reduction in Clinical Interview 
Schedule-Revised depression score in tocilizumab group 
compared with placebo; mean (SD) for outcome=15(3) 
based on a previous RCT of depression.42 We believe the 
actual sample size needed for the primary outcome will 
be smaller, as somatic symptoms are strongly influenced 
by inflammation.
randomisation and blinding
Participants will be randomly assigned to tocilizumab or 
normal saline group (1:1) using minimisation method to 
ensure that groups are comparable on somatic symptom 
severity and sex. Sealed Envelope, an external company, 
will do randomisation. Randomisation codes will be 
sent directly to the Central Pharmacy, Addenbrooke’s 
Hospital, Cambridge University Hospitals NHS Foun-
dation Trust, who will dispense tocilizumab or normal 
saline according to randomisation schedule. Infusions 
will be prepared and administered at a clinical research 
facility (CRF) in Cambridge Biomedical Campus by 
CRF staff. Infusion packs containing drug or placebo 
will be visually indistinguishable ensuring both partici-
pants and study team remain blind about allocation of 
intervention.
statistical analysis
The clinical trial data will be analysed using an intention-
to-treat approach. We will compare outcome measures 
between treatment and placebo groups controlling for 
baseline scores. This mechanistic experiment will focus 
on overall pattern of results rather than p values for 
individual tests of statistical significance. Analysis for 
the secondary observational study will compare psychi-
atric, cognitive and biomarkers between inflamed and 
non-inflamed groups using appropriate parametric and 
non-parametric statistical tests.
study ProCEdurE
Identification of potentially eligible participants
An overview of study procedures has been presented in 
figure 2. The study has been adopted by the National 
Institute for Health Research (NIHR) clinical research 
network (CRN) portfolio. Recruitment sites will include 
Cambridgeshire and Peterborough NHS Foundation Trust 
(CPFT), Norfolk and Suffolk NHS Foundation Trust and 
primary care general practices (GPs) in Cambridgeshire 
and Suffolk. In addition, we will advertise in social media 
and in the community. Potentially eligible participants 
will be identified directly by clinicians, and by electronic 
Table 1 Insight study inclusion and exclusion criteria
Group Inclusion criteria Exclusion criteria
All 
participants
 ► Provide informed consent.
 ► Understand written and spoken English.
 ► Able to consent to blood sampling.
 ► Willing to abstain from strenuous exercise for 
72 hours prior to assessment.
 ► Age: 20–65 years (inclusive).
 ► Diagnosis of depression: meet ICD-10 criteria 
at the time of assessment.
 ► Somatic symptom score: ≥7 at the time 
of eligibility based on Beck Depression 
Inventory-II items 4=lack of pleasure, 
15=loss of energy, 16=changes in 
sleeping pattern, 18=changed in appetite, 
19=concentration difficulty, 20=tiredness or 
fatigue and 21=loss of interest in sex.
 ► History of non/slow response to 
antidepressant: receiving treatment with an 
antidepressant at adequate dose (according 
to BNF) for at least 4 weeks.
 ► Current or lifetime diagnosis of bipolar disorder, psychotic 
disorder, personality disorder or eating disorder.
 ► Current suicidal thoughts or history of suicide attempt, 
deliberate self-harm, overdose within 6 months prior to 
eligibility assessment.
 ► History of alcohol or substance use disorder (abuse/
dependence) within 6 months prior to eligibility assessment.
 ► Pregnant or breast feeding.
 ► History of serious allergic reaction after any infusion.
 ► Current use of medication likely to compromise 
interpretation of immunological data (including, but not 
limited to, antibiotics, non-steroidal anti-inflammatory drugs, 
oral/injectable corticosteroids).
 ► Any major episode of infection requiring hospitalisation or 
treatment with intravenous antibiotics within 4 weeks of 
eligibility assessment.
 ► Presence or history of the following illnesses: recurrent 
bacterial, viral, fungal, mycobacterial or other opportunistic 
infections; unstable cardiac, pulmonary, renal, hepatic, 
endocrine, haematological or active infectious disease; 
rheumatic autoimmune disease, mixed connective 
tissue disease, scleroderma, polymyositis; uncontrolled 
hypertension.
 ► No history of chickenpox infection or no history of varicella 
zoster vaccination.
Intervention 
cohort
 ► Serum/plasma high-sensitivity C reactive 
protein level ≥3 mg/L.
 ► Current or past infection with tuberculosis (TB), hepatitis B, 
hepatitis C, HIV or Varicella Zoster Virus.
 ► History of severe allergic or anaphylactic reactions to 
human, humanised or murine monoclonal antibodies.
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search of clinical/research databases used by CPFT and 
GP surgeries. Participants will be first approached by 
their clinicians unless they had previously given consent 
to be contacted for research.
Eligibility assessment
Face-to-face assessment will be carried out to estab-
lish eligibility and to obtain informed consent. A blood 
sample will be collected for serum hs-CRP measurement. 
In addition, participants identified from primary care 
will be first screened using a questionnaire containing 
key inclusion/exclusion criteria and the Patient Health 
Questionnaire-9.43
baseline data collection
All participants (50 inflamed and 50 non-inflamed) will 
attend a face-to-face assessment comprising psychiatric 
measures, cognitive tasks and blood sampling. Please see 
table 2 for a list of all study measures. This will be the final 
study contact for non-inflamed participants. Inflamed 
participants will undergo further tests to establish safety/
eligibility to receive tocilizumab, which will include a 
chest X-ray and blood tests to exclude pregnancy and 
certain infections, such as TB, HIV. Eligible participants 
will be randomised and will be invited for infusion.
Intervention
Intravenous infusion of tocilizumab or normal saline will 
be given continuously over an hour at a CRF in Cambridge 
Biomedical Campus by trained clinical staff under the 
supervision of a designated study doctor. Participants will 
remain under clinical observation for a further 1-hour 
period after the end of infusion.
Table 2 Study measures
Domain Tool Source
Validated 
tool
Time of 
assessment
Sociodemographic/
lifestyle
Screening questionnaire Self-report Screening
Sociodemographic questionnaire Self-report Baseline
Antidepressant history and  concomitant 
treatment questionnaire
Self-report/general 
practice 
Baseline
Drug and alcohol questionnaire Self-report Baseline
Psychiatric Patient Health Questionnaire-9 Self-report ✓ Screening
Clinical Interview Schedule-Revised Self-report ✓ Eligibility
Beck Depression Inventory-II Self-report ✓ Eligibility, baseline,
follow-ups
Snaith-Hamilton Pleasure Scale 
Questionnaire
Self-report ✓ Baseline,
follow-ups
Multidimensional Fatigue Inventory Self-report ✓ Baseline,
follow-ups
Visual Analogue Scales for Subjective 
Feelings
Self-report Baseline,
follow-ups
Perceived Stress Scale Self-report ✓ Baseline
Cognitive National Adult Reading Scale for estimated 
premorbid IQ
Interviewer assessed ✓ Baseline,
follow-up 2
Cambridge Neuropsychological Test 
Automated Battery (CANTAB) reaction time
Computer task ✓ Baseline,
follow-up 2
Symbol coding task Computer/paper Baseline,
follow-up 2
CANTAB Rapid Visual Information 
Processing
Computer task ✓ Baseline,
follow-up 2
CANTAB Paired Associates Learning Computer task ✓ Baseline,
follow-up 2
Emotional categorisation and recall task Computer task ✓ Baseline,
follow-up 2
Biologic Inflammatory markers, cardiometabolic 
markers, IDO activation, white cell 
phenotyping
Laboratory tests Baseline,
follow-ups
Genetic Gene expression/genotyping Blood (RNA, DNA) Baseline,
follow-up 2
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Follow-up
Follow-up assessments will take place approximately 7, 14 
and 28 days after infusion, and will be similar to baseline 
data collection. Cognitive tasks will be administered only 
on day 14. At around 42 days after infusion, participants 
will be contacted by phone to provide final debrief at 
which point they will exit the study.
rIsk MAnAgEMEnt
depression-related risks
To minimise risk, all participants are required to be regis-
tered with a general practitioner, and give consent to 
access GP records to verify eligibility and to share clin-
ically relevant findings with their GP. If a participant 
becomes distressed during an interview or does not wish 
to continue for any reason, the researcher will stop the 
interview and liaise with the study doctor to decide on 
appropriate course of action. Participants will be assessed 
for suicidality during eligibility assessment. Those with 
serious suicidal thoughts or history of suicide attempt, 
deliberate self-harm, overdose in 6 months prior to eligi-
bility assessment will be excluded.
Procedure-related risks
Venepuncture
The study requires blood draw. Blood taking is associ-
ated with mild discomfort and bruising though serious 
side effects are rare. Efforts will be made to minimise 
risk. Blood taking will be performed by a nurse, doctor or 
research team member trained in venepuncture.
Chest X-ray
Participants in the intervention cohort will receive a chest 
X-ray to screen for TB with a typical effective radiation 
dose of 0.016 mSv. This X-ray is additional to any standard 
clinical care outside of the trial. The dose is equivalent to 
that received, on average in the UK, from natural sources 
of radiation in the environment every 3–10 days. All 
examinations will need to be completed in compliance 
with local Ionising Radiation Medical Exposure Regula-
tions Employer’s Procedures.
CRP levels
Participants will be informed of their serum hs-CRP level. 
The proposed threshold for defining participants as 
‘inflamed’ used in this study is serum CRP level ≥3 mg/L. 
Having serum hs-CRP level above this threshold is 
not necessarily a cause for concern. About 30% of the 
general population have serum CRP levels 3.0–9.9 mg/L, 
and about 10%–15% have levels>10 mg/L.44 Reasons for 
elevated CRP in the absence of an infection or chronic 
inflammatory illness could include obesity, smoking, 
alcohol use, lack of exercise, so knowledge of CRP levels 
might prompt participants to adopt a healthier lifestyle. 
If serum CRP level is very high (>20 mg/L) without 
any apparent explanation such as infection or chronic 
inflammatory illness, we will inform the GP and the 
participant will be excluded from the study.
Risks to research staff
When home visits or lone working are required, staff 
will follow local safety procedures. Home visits will be 
conducted in pairs whenever possible for first visits.
safety considerations for infusion and monitoring of adverse 
reaction
Before infusion
Participants will be selected based on strict inclusion and 
exclusion criteria to minimise risk. In addition, we will 
carry out blood/other tests to exclude TB, HIV, VZV, 
hepatitis B and C because, though unlikely after a single 
dose, tocilizumab infusion could make these infections 
worse. Female participants of childbearing age will be 
given blood test for pregnancy. Participants who are sexu-
ally active will be asked to use contraception for 6 weeks 
after infusion. Male participants will be also asked not to 
donate sperm samples for 6 weeks after infusion.
During infusion
Infusions will be given under supervision of a designated 
study doctor. Participants will be monitored throughout 
the duration of infusion; vital signs and possible side 
effects will be recorded. Any immediate adverse events 
will be managed in line with the Addenbrooke’s Clinical 
Research Centre adverse event policy (ACRC/SOP018).
After infusion
Participants will remain under observation for a 1-hour 
period after infusion. Participants will be advised to seek 
help through GP or hospital accident and emergency 
(A&E) department if they feel unwell after leaving the 
hospital. Before leaving the CRF, participants will be given 
an information sheet containing a telephone number 
their health professionals can call. If necessary, we will 
unblind the participant and inform their health profes-
sional whether the participant had received tocilizumab 
or normal saline. Adverse reactions will be recorded at 
every follow-up and at final contact over the phone on day 
42 after infusion. The expected time for complete elimi-
nation of tocilizumab from the system is approximately 42 
days after a single infusion.45
EthICs And dIssEMInAtIon
The study will be conducted in accordance with guide-
lines from the REC, Health Research Authority (HRA) 
and local Research and Development (R&D) depart-
ments. The study team will prepare protocol amend-
ments as required and ethics approval will be sought 
before implementing any changes to the approved 
protocol. The ISRCTN Trial Registry and the Research 
Governance Office will be informed of any amendments 
to the protocol.
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Consent
Informed consent will be obtained for screening and 
for participation in the study. This will include consent 
to randomise, to contact GP to inform about participa-
tion in study, to access GP/psychiatric records to verify 
medical history to establish eligibility and to inform GP 
any results/outcomes as necessary. Consent for addi-
tional tests to establish safety for tocilizumab infusion 
and for storing biological samples will be also obtained. 
Participants have the option to opt in to being contacted 
for future studies.
study management
The Chief Investigator (CI) will have overall responsi-
bility for the study. A named principal investigator (PI) 
will take clinical responsibility for the research team at 
each site. The CI will meet the study team regularly to 
discuss any issues. The study does not require the formal 
arrangement of a steering committee, because, according 
to HRA, it is not a Clinical Trial of an Investigational 
Medicinal Product. However, to enhance monitoring of 
study, a study management group has been set up, which 
includes academic and clinical experts in psychiatry, 
rheumatology, neuroscience and immunology.
data management and retention of samples
All potential participants will be assigned a unique 
study-specific participant ID number. All data, including 
personal details identifying individuals and anonymised 
data, will be subject to good practice as laid down in the 
Data Protection Act. Each stage of inviting, informing 
and assessing a particular participant is tracked so that 
their (anonymised) current status within the study is 
known and assessment and other appointment dates are 
forecasted. This information is held on the secure, pass-
word-protected database. Anonymised data from assess-
ments will be uploaded to the secure, password-protected 
database using web-based data entry systems, transcribing 
from paper copy as necessary. Minimal personal data (eg, 
date of birth, sex) could be indexed by each participant’s 
unique ID number.
Blood samples collected in this study may be stored for 
up to 10 years after the completion of the study for addi-
tional research. Stored samples will be coded throughout 
the sample storage and analysis process and will not be 
labelled with personal identifiers. Participants may with-
draw their consent for their samples to be stored for 
future research.
dissemination plan
Study findings will be published in peer-review journals. 
Publications will conform to the guidelines of the Inter-
national Committee of Medical Journal Editors. Findings 
will be disseminated at conferences, departmental talks 
and other scientific meetings. Further dissemination will 
take place via social and traditional media.
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